You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Wearable modular high-density diffuse optical tomography
SBC: EsperImage LLC Topic: 103Project Summary: EsperImage, a startup company out of Washington University (WUSTL), will develop high fidelity, wearable, optical technology that transcends limitations of both previous optical neuroimaging and magnetic resonance imaging (MRI) tools to provide naturalistic brain imaging in adults and children. A neurodevelopmental disorder affecting 1/54 children in the general population, autism ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Utility of a Novel Anthracycline Analog in Psoriasis
SBC: GEM Pharmaceuticals Topic: N/ADESCRIPTION (provided by applicant): Psoriasis is a common immune-mediated disease that affects approximately 2% of the US and European populations and significantly impacts the quality of life. T cells are recognized as primary mediators of the disease and new generation therapies aimed at eliminating reactive T cells or interfering with the immunologic cascade caused by their activation have bee ...
STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health -
Using siRNAs against tau circular RNAs as a rational therapy for Alzheimer's disease
SBC: CircCure Corporation Topic: RSummary:The formation of neurofibrillary tangles (NFT) formed by aggregation of the microtubule-associated protein tau (MAPT) is a hallmark of Alzheimer’s disease (AD) and the likely cause of neuronal death. Currently, there are no rational treatments available that directly target NFT formation and thus address the direct molecular cause for AD. Based on our academic research, we will develop a ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Use of mimotope vaccine technology to develop vaccines against bacterial pathogens
SBC: ZenVax LLC Topic: NIAIDABSTRACT This Small Business Technology TransferSTTRPhase I proposal is in response toNIH NIAID Research Topics in Division of Microbiology and Infectious Diseases and Bacteriology and Mycology BranchVaccine for prevention of human Q feverQ fever is a worldwide zoonotic disease that is caused by the obligate intracellular Gram negative bacteriumCoxiella burnetiiThe highly infectious nature of Cbur ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Universal affinity membrane chromatography for rapid, one-step purification of proteins
SBC: TriAltus Bioscience, LLC Topic: 400Project Summary The goal of this STTR Phase I project is to demonstrate the feasibility of developing the first universal affinity membrane for the rapid, selective, one-step purification of difficult-to-purify proteins. Despite the urgency for expanding the application of gene editing systems and accelerating vaccine and antibody test development, the rapid purification of critical proteins such ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Ultra-soft atomic force microscope (USAFM) technology using nano-cantilevers for
SBC: NAUGANNEEDLES, LLC Topic: N/ADESCRIPTION (provided by applicant): NaugaNeedles LLC in collaboration with researchers from Purdue University are proposing to develop an advanced new Ultra-Soft Atomic Force Microscope (USAFM). This USAFM can gently create images of soft biological samples in buffer solutions with sub-picoNewton (pN) forces and sub-nm lateral resolution. This new AFM technology will have a high-bandwidth to ensu ...
STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health -
Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study
SBC: VASCULOX, INC. Topic: NCIDESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a don't eat me signal to macrophages via SIRPa, an inhibitory receptor that prevents phagocytosis of CD47-bearing ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Translational imaging tools to nondestructively measure nephron mass
SBC: XN BIOTECHNOLOGIES LLC Topic: 400PROJECT SUMMARY This work is aimed to improve outcomes in patients with kidney disease through improved diagnostics. Nephron mass is a measure of the functional capacity of the kidney. Its measurement could be transformative in detecting susceptibility to and progression of kidney diseases. However, no clinical tools or assays currently exist to directly measure nephron mass. We have developed too ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Transgenic plant cells as source of hepatoprotective dr*
SBC: NAPROGENIX, INC. Topic: N/ATransgenic plant cells as source of hepatoprotective drugs. Alcoholic liver damage (ALD) is among the ten most common causes of death in the USA. The liver may be uniquely sensitive because it metabolizes ethanol at a high rate. This generates acetaldehyde intracellularly, damaging cell components directly, and/or inducing apoptotic cell death. Although some plant natural products are protective i ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Transgenic plant cells as a source of hepatoprotective drugs
SBC: NAPROGENIX, INC. Topic: N/ADESCRIPTION (provided by applicant): Alcoholic liver damage (ALD) is among the top ten causes of death in the USA, but existing therapeutic interventions are relatively ineffective. Hepatocytes are susceptible to damage probably because they have a high level of alcohol dehydrogenase (ADH) which metabolizes alcohol to form acetaldehyde and reactive oxygen species (ROS), which are both cytotoxic. C ...
STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health